Abstract:
An impact instrument (200) for delivering an impulse to an object. The impact instrument (200) may include an impact surface (202) for contacting the object and an elongated member (204) extending from the impact surface (202) that terminates in an end. The elongated member (204) may include a grasping region in the vicinity of the end. When the instrument is grasped within the grasping region, the center of percussion of the instrument preferably coincides with the impact surface (202). The instrument may also contain pivoting grasping member disposed on the elongated member. A cavity (212, 214, 216, 218, 220) is preferably formed between the grasping member (206) and the elongated member (204) and may contain compressible material. The grasping member (206) may rigidly contact the elongated member (204) at an ideal pivot point (208). The grasping member (206) is preferably adapted to pivot with respect to the elongated member (204) at the ideal pivot point (208). The pivoting of the grasping member (206) preferably increases the amount of impulse delivered to an object, decreases vibration experienced by the user of the instrument, and reduces counter-rotational forces imparted from the instrument to the user. The impact instrument (200) may be a hammer, ax, golf club, tennis racket, or similar device.
Abstract:
The breakpoints of the pericentric inversion of chromosome 16 have been cloned. Two genes, one at each breakpoint, have also been identified, as well as several forms of the inversion 16 fusion gene. Diagnostic applications for chromosome 16 abnormalities and, particularly acute myeloid leukemia, are also within the scope of the present invention. The figure is a diagrammatic representation of the locations of the human genomic chromosome 16p content of hybrid cells and recombinant clones.
Abstract:
Human and murine tissue transglutaminases are cloned, sequenced and expressed. The tissue transglutaminases herein are useful for, inter alia, therapeutic wound repair, stabilizing food preparations, and markers for identifying agents which act as agonists or antagonists of cellular apoptosis.
Abstract:
Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy -induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
Abstract:
A method of forming titanium boron alloys includes forming a mixture of elemental titanium with elemental boron and heating the mixture with a laser, wherein a power level of the laser is set such that reaction of the elemental titanium with the elemental boron to form a titanium-boron alloy is initiated and self-sustaining.
Abstract:
Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
Abstract:
Disclosed herein are compounds and compositions useful in the treatment of GLS I mediated diseases, such as cancer, having the structure of Formula I. Methods of inhibition GLS I activity in a human or animal subject are also provided. Accordingly, the inventors herein disclose new compositions and methods for inhibiting glutaminase activity.
Abstract:
The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.
Abstract:
The present disclosure generally relates to cache memory systems and/or techniques to identify dead cache blocks in cache memory systems. Example systems may include a cache memory that is accessible by a cache client. The cache memory may include a plurality of storage locations for a first cache block, with a most recently used position location in the cache memory. A cache controller may be configured to predict whether the first cache block stored in the cache memory is identified as a dead cache block based on a cache burst of the first cache block. The cache burst may comprise a first access of the first cache block by a cache client and any subsequent contiguous accesses of the first cache block following the first access by the cache client while the first cache block is in a most recently used position of the cache set.
Abstract:
The present disclosure generally relates to systems for routing data across a multinodal network. Example systems include a multinodal array having a plurality of nodes and a plurality of physical communication channels connecting the nodes. At least one of the physical communication channels may be configured to route data from a first node to two or more other destination nodes of the plurality of nodes. The present disclosure also generally relates to methods for routing data across a multinodal network and computer accessible mediums having stored thereon computer executable instructions for performing techniques for routing data across a multinodal network.